CNBC’s Meg Tirrell sits down with Gilead CEO Daniel O’Day amid the American Society of Clinical Oncology conference in Chicago to discuss the company’s latest data surrounding its cancer drug Trodelvy.
Gilead CEO Daniel O’Day breaks down new Trodelvy data in breast cancer patients
Tweet on Twitter
Share on Facebook
Pinterest
